Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mAb104-DM1
- Development stage
- Preclinical
- Lead developer
- Olivia Newton-John Cancer Research Institute
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal
01
Overview
**mAb104-DM1** is a preclinical HER2-targeted antibody-drug conjugate composed of the murine IgG1 monoclonal antibody mAb104 linked through an SMCC linker to the maytansinoid microtubule inhibitor DM1. mAb104 recognizes a tumour-selective conformational epitope on human epidermal growth factor receptor 2 that is exposed on tumour cells while showing minimal normal-tissue binding. Following HER2 binding and tumour-cell internalisation, intracellular release or processing of the DM1 conjugate disrupts microtubule function and inhibits cell division. The ADC was prepared by Levena Biopharma with a drug-to-antibody ratio of approximately 3.4 to 3.7 and has shown dose-dependent cytotoxicity and antitumour activity in preclinical HER2-expressing cancer models.
- Other names
- Mab104-DM1Mab-104-DM1Mab 104-DM1
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on mAb104-DM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mAb104-DM1.